Advocating for fairness, transparency, and integrity across the pharmaceutical supply chain.
LEARN MORE
This standard is reflected in how we engage with partners, providers, and policymakers.
View our published insights, policy contributions, and formal filings.
Submitted comment to the Department of Commerce for review during its Section 232 National Security Investigation into pharmaceutical and pharmaceutical ingredient imports.
Regarding the Federal Trade Commission (FTC) and U.S. Department of Health and Human Services (HHS) Solicitation of Public Comment to Understand Lack of Competition and Contracting Practices that May be Contributing to Drug Shortages
The great American drug shortage isn't an accident, its artificial
Submitted comments on FDA’s proposed rule regarding National Standards for the Licensure of Wholesale Drug Distributors and Third-Party Logistics Providers
Submitted comments on two FDA draft guidance documents related to the Drug Supply Chain Security Act: (i) definitions of suspect and illegitimate products for verification obligations, and (ii) enhanced drug distribution security at the package level.
Analysis of the U.S. supply chain for critical drugs and medical devices, potential public health security or national security risks, existing supply chain information gaps and the potential economic impact of increased domestic manufacturing
Integer tempus, elit in laoreet posuere, lectus neque blandit dui, et placerat urna diam mattis orci. Mauris id fermentum nulla. Donec eget risus diam. Nullam sit amet nisi condimentum erat iaculis auctor. Maecenas non leo laoreet, condimentum lorem nec, vulputate massa.